The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally advanced pancreatic cancer, in combination with gemcitabine and nab- paclitaxel.
The FDA has approved a first-of-its-kind portable, noninvasive device that delivers alternating electrical fields for the treatment of locally advanced pancreatic cancer.Optune Pax (Novocure) releases ...
The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results